Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
At the 7th Annual General Meeting on August 26, 2026, all five resolutions were approved by shareholders. These included the adoption of the audited financial statements for the fiscal year ending March 31, 2026, the declaration of a final dividend of ₹2.50 per equity share, the re-appointment of directors Shyam S. Bhartia and Priyavrat Bhartia, and the ratification of the cost auditor's remuneration.
On August 28, 2026, the Jubilant Ingrevia Employees Welfare Trust sold 5,622 equity shares valued at ₹3,842,637 through an Employee Stock Option Plan (ESOP) on the NSE. This transaction reduced the trust's holding from 1,539,617 shares (0.0097%) to 1,533,995 shares (0.0096%).
As of September 18, 2026, Jubilant Ingrevia's stock has experienced varied returns across different timeframes. The stock saw a return of -1% over the last day, -14% over the last month, and -12% over the last year. Year-to-date, the return was also -12%. Longer-term returns include -6% over 5 days and -10% over 10 days, while the return over the last 6 months was positive at 8%.
As of September 18, 2026, key technical levels for Jubilant Ingrevia are as follows: Support levels are identified at ₹618.62 (1.01% below current price), ₹615.00 (1.58% below), ₹612.33 (2.01% below), and ₹600.34 (3.93% below). Resistance levels are noted at ₹625.93 (0.17% above current price), ₹632.22 (1.17% above), ₹639.53 (2.34% above), and ₹645.82 (3.35% above).
As of 18 Sept 2026, 03:30 pm
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Downward price movement of 2.99 standard deviations recorded on 2026-09-15.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹1,300.27 crore | ₹1,178.65 crore | ₹1,050.99 crore | ₹1,120.73 crore | ₹1,037.95 crore |
| Finance Costs | PEAK₹17.43 crore | ₹11.81 crore | ₹12.46 crore | ₹12.16 crore | ₹12.69 crore |
| Profit Before Tax | PEAK₹140.89 crore | ₹111.73 crore | ₹65.43 crore | ₹92.94 crore | ₹99.83 crore |
| Tax Expense | PEAK₹35.04 crore | ₹25.27 crore | ₹18.51 crore | ₹23.39 crore | ₹24.67 crore |
| Profit Loss For Period | PEAK₹105.82 crore | ₹86.44 crore | ₹46.90 crore | ₹69.47 crore | ₹75.10 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | PEAK₹6.70 per share | ₹5.47 per share | ₹2.97 per share | ₹4.40 per share | ₹4.75 per share |
Jubilant Ingrevia Ltd. reported higher revenue and profit for the first quarter of fiscal 2027 ended 30 June 2026. Revenue from operations rose 25.27% year‑on‑year to ₹1,300.27 crore, while profit before tax grew 41.13% to ₹140.89 crore, driving an expansion in profit margins. Finance costs increased sharply, but the growth in earnings outpaced the rise in expenses.
Revenue from operations reached ₹1,300.27 crore, a 10.32% increase from ₹1,178.65 crore in the preceding quarter and a 25.27% increase from ₹1,037.95 crore in the same quarter a year earlier. The quarter‑on‑quarter growth followed a larger sequential rise in the prior quarter.
The first quarter of fiscal 2027 delivered broad‑based revenue and profit growth, with both profit‑before‑tax and net profit margins expanding even as finance costs climbed. Earnings per share reached ₹6.70, the highest level among the past five quarters.
Exchange disclosures and regulatory announcements for Jubilant Ingrevia.
On 2026-08-28, Jubilant Ingrevia Employees Welfare Trust sold 5,622 equity shares (value INR 3,842,637) via ESOP on NSE, reducing its holding from 1,539,617 shares (0.0097%) to 1,533,995 shares (0.0096%).
Jubilant Ingrevia Limited held its 7th Annual General Meeting on August 26, 2026, via video conferencing, where all five resolutions were passed with the requisite majority. The resolutions included the adoption of audited financial statements for FY ended March 31, 2026, declaration of a final dividend of Rs. 2.50 per equity share, re-appointment of directors Shyam S. Bhartia and Priyavrat Bhartia, and ratification of cost auditor's remuneration.
MEETING DATE : 26-AUG-2026
Jubilant Ingrevia Limited has informed the Exchange about Proceedings and Voting Results of the 7th Annual General Meeting held on August 26, 2026 along with Scrutinizer Report pursuant to Regulation 30 & 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) |SUBJECT: General Updates
As of March 31, 2026, promoter and promoter group held 45.22% of Jubilant Ingrevia Limited, public held 53.79%, and non-promoter non-public (employee benefit trusts) held 0.98%. Key public shareholders included HSB Trustee Company PL & HS Trustee Company PL (19.00%), SPB Trustee Company PL & SS Trustee Company PL (18.36%), and MAV Management Advisors LLP (3.15%). Among mutual funds, DSP Small Cap Fund held 8.93%, Kotak Small Cap Fund 2.94%, and Bandhan Small Cap Fund 2.28%. Foreign portfolio investors (Category I and II) held 6.49% combined. The percentage of limits utilized for foreign investment was 10.79% as of December 31, 2025, down from 11.82% as of March 31, 2025.
JUBLINGREA|JUBILANT INGREVIA LIMITED|Original|Regulation 7 (2)|IT_19288_WebXMLFile_20260825_182720319.xml|IT_19288_20260825_182720355_WEB.html|5475|23493|-
On August 18, 2026, Jubilant Ingrevia Limited announced its acquisition of a 40% stake in Zettaone Technologies India Private Limited, an integrated electronics design and manufacturing platform, for a cash consideration of INR 1,892,000,000. The acquisition will occur in two tranches, with the first expected to close by November 2026 and the second by September 2027. Zettaone reported a turnover of INR 981,000,000, profit after tax of INR 60,900,000, and net worth of INR 112,100,000 for the financial year 2025-2026.
On August 18, 2026, the Board of Directors of Jubilant Ingrevia Limited approved a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for approximately ₹189.2 crore in cash consideration. The transaction, which will make Zettaone an associate company, is structured in two tranches expected to close by November 2026 and September 2027 respectively. This acquisition aligns with Jubilant Ingrevia's Pinnacle growth strategy to expand its presence in the Electronics Development and Manufacturing Services (EDMS) space.
Recent market and company developments associated with Jubilant Ingrevia.
India's semiconductor sector has seen stock price declines of up to 71% in the last one year after the initial hype. Opportunities lie in assembly, testing and domestic manufacturing, but significant risks and high valuations could hinder long-term investor returns.
Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Shiprocket, ONGC, Aster DM Quality Care, Behari Lal Engineering, RailTel Corp, Atlanta Electricals, Hindustan Zinc, HG Infra, Jubilant Ingrevia, Interarch Building Solutions, Krystal Integrated Services, Shilpa Medicare, Ducon Infratechnologies, Exide Industries
Jubilant Ingrevia,Jubilant Ingrevia share price live today
In a significant move, Jubilant Ingrevia will take a 40% stake in Zettaone Technologies for Rs 189.2 crore. This acquisition is expected to bolster Jubilant's position in the electronics value chain. Zettaone Technologies, with its integrated electronics design and manufacturing prowess, will see the deal finalized in two stages by September 2027, aligning with Jubilant Ingrevia's strategic growth in the EDMS industry.
Jubilant Ingrevia's shares are expected to draw interest as it announced a 40% acquisition of Zettaone Technologies for ₹189.2 crore. This partnership aims to strengthen capabilities in the electronics and semiconductor sectors, enhancing long-term value creation.
The specialty chemicals company says Zettaone’s PCB design and manufacturing capabilities will complement its semiconductor chemicals business and expand its presence across the electronics value chain.
The issue closes on July 27, 2026, with shares scheduled to list on the BSE and NSE.
Q1 Results LIVE Updates: Three Nifty 50 companies, Eternal, Dr. Reddy's Laboratories and Nestle India, are reporting their earnings today. dani Green Energy, BPCL, Adani Power, CIE Automotive, CSB Bank, Waterways Leisure Tourism, HEG, HPCL, HFCL, IIFL Finance, JSW Energy, IndusInd Bank, United Spirits are among the other results scheduled for today. Also watch for result reactions from stocks like Bandhan Bank, JSW Infra, Indian Hotels and many others. Watch this space for all the LIVE updates.
Comprehensive Section Breakdown for Jubilant Ingrevia
Strategic Vision: Integrated provider of life science ingredients and innovative solutions.
• Integrated chemistry platforms
• Versatile manufacturing assets
• Backward and forward integration across the value chain
• Alignment with global manufacturing shifts to cost-efficient markets
Profit before tax improved to ₹140.89 crore, up 26.10% from ₹111.73 crore in the previous quarter and 41.13% from ₹99.83 crore a year ago. Net profit (profit for the period) rose 22.42% sequentially and 40.91% year‑on‑year to ₹105.82 crore. Basic earnings per share climbed to ₹6.70, compared with ₹5.47 in the fourth quarter and ₹4.75 in the same quarter last year.
Profit growth outpaced revenue growth, lifting margins. The profit‑before‑tax margin widened to 10.84% from 9.48% in the previous quarter and 9.62% a year ago. The net profit margin rose to 8.14% from 7.33% and 7.24%, respectively.
Finance costs jumped to ₹17.43 crore, a 47.59% increase from ₹11.81 crore in the previous quarter and 37.35% higher than ₹12.69 crore a year earlier. Despite this, the overall rise in profit margins showed that earnings growth absorbed the higher interest expense.
Tax expense rose to ₹35.04 crore, up 38.66% sequentially and 42.03% year‑on‑year. The effective tax rate (tax expense divided by profit before tax) came in at 24.87%, compared with 22.62% in the fourth quarter and 24.71% a year ago.
Category: Manufacturing
This segment comprises Bio-Pyridine & Bio-Picolines, Fine Chemicals, and CDMO services, utilizing versatile manufacturing assets and chemistry expertise to provide building blocks and custom solutions.
Category: B2B Services
This business supports brands in human and animal nutrition by providing science-backed ingredients and tailored formulations for food, feed, pharmaceutical, and personal care products.
Category: Manufacturing
This segment delivers essential building blocks for various industries, offering acetyl and ketene–based products to ensure a reliable, large-scale supply for critical upstream chemistry.
Core Thesis: The company's business model emphasizes backward and forward integration across its value chain, leveraging integrated chemistry platforms.
• Integrated Value Chain: The business model emphasizes backward and forward integration across its value chain to deliver solutions. • Chemistry Expertise: The company utilizes versatile manufacturing assets and chemistry expertise to provide building blocks, high-value intermediates, and custom synthesis solutions. • Global Reach: The company serves a broad customer base in 63 countries, with a significant presence in key international markets.